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ABSTRACT  
Dailey, Emma, M.S., Spring 2020                           Speech-Language Pathology  
Programmatic Desensitization of the Cough Reflex in Patients with Refractory Chronic Cough  
Chairperson:  Laurie Slovarp, Ph.D, CCC-SLP 
 
Aim: The purpose of this blinded, randomized, placebo-controlled pilot clinical trial was to determine 
the potential of treating refractory chronic cough (RCC) using a progressive desensitization model paired 
with behavioral cough suppression.  
Methods: Twelve adults with chronic cough who had failed behavioral cough treatment enrolled in and 
completed the study. Participants were randomly assigned to a treatment (n=8) or placebo group (n=4). 
The study consisted of three phases. During Phase I, participants completed baseline testing, including 
cough sensitivity testing with capsaicin, the Leicester Cough Questionnaire (LCQ), urge-to-cough-testing, 
and 24-hour cough frequency testing. During Phase II, participants practiced behavioral cough 
suppression while receiving a cough stimulant, capsaicin, via nebulizer across six sessions. The treatment 
group received progressive doses of capsaicin, while the placebo group received one, consistent, low 
level dose of capsaicin. During Phase III, cough outcomes were repeated at one-week and three-weeks 
post-treatment.  The Mann-Whitney U test was used to determine between-group differences on 
change scores.  The Friedman test followed by pair-wise comparisons with a Bonferroni correction was 
used to analyze change across time for the entire sample.  
Results: A Mann Whitney U test demonstrated weak evidence for differences between the treatment 
group (n=8) and placebo group (n = 4) between baseline and one-week post-treatment for the LCQ (p = 
0.23), UTC testing for total coughs (p = 0.107) and mean reported UTC (p = .184) that favored the 
treatment group. Cough sensitivity results were variable with a significant increase in capsaicin 
tolerance (i.e., reduction in cough sensitivity) at one-week post that favored the treatment group (p = 
.016); however at three-weeks post, capsaicin tolerance was higher for the placebo group (mean rank = 
8.5) then the treatment group (mean rank = 5.5). A Friedman test on the entire sample revealed strong 
evidence for improvement at one-week post for the LCQ, (p = .001), UTC testing for total coughs (p = 
.016) and mean reported UTC (p = .006), but not cough sensitivity (p = .689). There was no evidence of a 
change between one-week post and three-weeks post (p =.933).  
Conclusions: This study investigated the use of progression desensitization with capsaicin paired with 
behavioral cough suppression for individuals with RCC due to hypersensitivity. Both groups experienced 
improved quality of life, perceived UTC during UTC testing, and cough frequency during UTC testing 
following treatment.  No change in cough sensitivity was demonstrated; however, high response 
variability suggests questionable reliability of cough sensitivity testing. Though the study was limited by 
small sample size and unreliable cough sensitivity results, both groups improved significantly suggesting 
the need for further research.  Investigation is needed to examine patient compliance and refine 
placebo group methodology to determine the treatment factors that impact outcomes.  
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Introduction 
Chronic cough (CC), defined as a cough lasting longer than eight weeks, is an increasingly 
recognized disorder (1). Patients with CC experience significant psychosocial stress and impairments of 
quality of life (2-4). Despite extensive testing and medication trials, 10-20% of patients with CC do not 
respond to medical treatment and are said to have refractory chronic cough (RCC) (5-8). Distinctive 
features of RCC include a non-productive cough, abnormal environmental triggers such as smoke, 
fumes, and dust, or physiological stimuli, such as talking or laughing (9). These characteristics suggest a 
heightened sensory response in the airway (6, 9). Enhanced sensitivity has led this subset of RCC to be 
called cough hypersensitivity syndrome (CHS) (1, 6, 10, 11). It is hypothesized that patients with CHS 
experience an initial peripheral sensitization of the airway causing a cough, such as an inflammatory 
upper respiratory illness; neuroinflammatory receptors then become centralized, leading to long-term 
cough ( (1, 6). Research has shown that this hypersensitivity is, at least in part, a result of disordered 
afferent sensory neuron receptors in the airway. Specifically, over expression of transient receptor 
potential vanilloid type 1 (TRPV1) on C-fibers (1, 6, 12-17).  
Several studies have shown that behavioral therapy, typically provided by a speech-language 
pathologist, for RCC is efficacious  (18-21). Three randomized control trials (18-22) as well as a number 
of within-subject design studies (23-26) have examined the effect of the therapy using various cough 
outcome measures. All the studies reported improvement in cough status after treatment, measured by 
an increase in self-reported quality-of-life, and a decrease in cough symptoms and cough frequency. 
Many terms are currently used to describe behavioral therapy for cough throughout the literature. The 
term behavioral cough suppression therapy (BCST) is used in this manuscript because it is descriptive of 
the therapy and clearly delineates it from medical treatment (5, 27).  
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Though BCST has been performed by a variety of professionals, speech-language pathologists 
(SLPs) have become the main advocates for BCST due to their role as specialists in voice and upper 
airway disorders (5, 18, 28). In BCST, clients are educated on cough hypersensitivity and the rationale for 
cough suppression,  behavioral management of medical conditions that commonly contribute to cough 
(e.g., reflux and post-nasal drip), vocal hygiene practices, and resonant voice therapy and respiratory 
retraining if applicable (e.g., for muscle tension dysphonia or induced laryngeal obstruction).  The 
primary component of BCST is teaching patients various cough suppression strategies. Although 
improving control of one’s cough is of benefit to patients, the primary goal of cough suppression is not 
to make patients good at suppressing their cough. Rather, the goal of cough suppression is to stimulate 
a reduction in cough sensitivity through a neuroplastic mechanism. BCST is designed to capitalize on the 
lose-it portion of the use-it-or-lose it principle of neuroplasticity to reduce hypersensitivity of the airway 
(19, 29, 30). Avoiding cough when an urge-to-cough is triggered theoretically decreases the afferent 
cough signal, and eventually reduces sensitivity. This theory is consistent with results of several studies 
that show a decrease in cough sensitivity following BCST (19, 22, 23).  Participants typically require only 
1-4 weekly sessions with a BCST provider, and most experience a reduction in cough symptoms within 1-
2 weeks (10, 19, 31). 
Despite the high success of BCST for many individuals with RCC, the therapy does not improve 
cough for every patient, and of those who benefit from the therapy, an estimated 11%- 16% do not have 
full resolution of their cough (18, 28). Patients who are unable to suppress their cough, whether due to 
non-compliance in using cough suppression strategies, or inability to suppress when exposed to strong 
triggers within their environment, are the most unlikely to benefit from the therapy. We hypothesize 
these patients may benefit from a treatment model combining behavioral cough suppression with 
repeated exposure to progressive doses of a controllable cough stimulant strong enough to elicit an 
urge-to-cough, but weak enough to allow for successful cough suppression. The safety, reproducibility, 
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and straightforward dilution of aerosolized capsaicin make it an ideal cough stimulant for this purpose. 
We recently demonstrated proof-of-concept of this hypothesis with five healthy participants who 
completed six treatment sessions over a two-week period (27). Every participant demonstrated a 
significant decrease in cough sensitivity as tested by capsaicin cough challenge testing before and after 
treatment (27). Participants maintained these improvements at three-weeks post-treatment.  
 The current study investigates this treatment model, which we term cough desensitization 
treatment (CDT), on patients with RCC who have not had a sufficient response to BCST. We 
hypothesized that exposure to progressive doses of aerosolized capsaicin while implementing 
behavioral cough suppression strategies (i.e., CDT) would result in a change in cough reflex sensitivity, 
perceived urge-to-cough, cough frequency, and cough-related quality of life. The research questions for 
this study were:  
1. Does exposure to progressive doses of aerosolized capsaicin while implementing behavioral 
cough suppression strategies result in a change in cough reflex sensitivity or cough frequency? 
2. Does exposure to progressive doses of aerosolized capsaicin while implementing behavioral 
cough suppression strategies result in a change in cough-related quality of life? 
Methodology 
Design and Participants 
This randomized, placebo-controlled trial investigated the effects of cough desensitization 
therapy (CDT), a clinically controlled application for the treatment of RCC, which is a modification of 
BCST. The study was approved by both the Food and Drug Administration (FDA; Investigational New 
Drug (IND) #142148) and the University of Montana Institutional Review Board (IRB #188-18) (see 
Appendix A for informed consent).  Twelve adults with RCC who failed medical treatment and did not 
have full resolution of cough with BCST completed the study. Participants were recruited from two 
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pools: local speech therapy clinics that provide BCST or those who completed a previous survey study 
about BCST. All participants scored no greater than 16 on the Leicester Cough Questionnaire1 after a 
course of BCST, indicating their cough had not fully resolved. In addition to treatment of cough, inclusion 
criteria also included normal chest x-ray, pulmonary function testing, and laryngoscopy. Exclusion 
criteria were as follows: current smoker, pregnant or trying to become pregnant, diagnosis of a 
respiratory or pulmonary condition (i.e. asthma, COPD, emphysema, etc.), and not currently or recently 
on ACE-inhibitor medication.  
Participants were randomly assigned to either a treatment or placebo group, and blinded to 
which group they were in. Given that information already exists in literature for a placebo improvement 
rate of 10—20% and the improvement rate of the treatment group is the main estimate of interest, we 
sought to assign approximately 60% of participants to the treatment group and 40% to the placebo 
group (32, 33).  Participants were given the rationale for the placebo group and were told the active 
substance was designed to enhance BCST. They were not told that the active substance was capsaicin. 
Participants were informed that if they were selected for the placebo group, and if the active treatment 
was found to be efficacious, they would be eligible for the active treatment following their completion 
of the study. Baseline and post-treatment assessors were also blinded to group assignment. 
The study consisted of three phases: (1) baseline testing, (2) cough treatment sessions twice per 
week for three weeks, and (3) two post-treatment testing sessions administered at one-week, and 
three-weeks post-treatment.  
Capsaicin Quality Control  
 
1 The LCQ is a 19-item questionnaire that assesses cough-related quality-of-life. The total score range is 3-21, a 
higher score indicates a better quality of life. See Appendix B for copy.  
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Pharmaceutical grade capsaicin, in powder form, was purchased from Formosa Laboratories Inc. 
(Formosa Laboratories, Inc. Taoyuan, Taiwan 338) and diluted in a sterile environment according to 
standard procedures designed by the European Respiratory Society (34, 35). The capsaicin was diluted 
with 95% ethanol to make two stock solutions of concentrations 0.01, and 0.001 Molar. A sample of 
each stock solution was sent to Toxikon laboratories, which confirmed sterility. In addition, stock 
solution stability was confirmed with periodic reverse-phase high-performance liquid chromatographic 
(RP-HPLC) assay (36) across a six month period.  Stock solutions were discarded after six months of use. 
The stock solutions were diluted with inhalation-safe sodium chloride to the following concentrations: 
0.49, 0.98, 1.95, 3.91, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, 675, 750, and 1000 M. Dilutions were made 
under sterile conditions (i.e., passed through a Milipore 2M filter and made in a hood with airflow 
filtration) within 24 hours of use. Stock solutions and dilutions were protected from UV light and stored 
in a temperature-controlled, 4 C refrigerator in order to reduce degradation of the solution.  
Outcome Measures  
Outcome measures were administered at baseline, and one- week, and three- weeks post-
treatment. Outcome measures included capsaicin cough challenge testing (i.e., to measure cough 
sensitivity), the Leicester Cough Questionnaire (LCQ), urge-to-cough (UTC) testing, and 24-hour cough 
frequency monitoring using the Leicester Cough Monitor (37, 38).  
Cough Challenge Testing. Capsaicin cough challenge testing procedures, as recommended by 
the European Respiratory Society (39) and approved by the FDA (IND #142148), were followed to 
measure cough sensitivity in participants before and after treatment (34, 40, 41) (see Appendix C for 
cough challenge testing forms). Pulmonary function testing was completed before and after each testing 
session to ensure cough challenge testing did not negatively impact pulmonary function. Following 
spirometry, participants were exposed to doubling concentrations of capsaicin dilutions via single inhale, 
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starting with 0.49 M, through the Koko Digidoser with DeVilbliss nebulizer. Participants were given 
scripted verbal instructions on the procedure and instructed not to attempt to suppress any urge-to-
cough. Testing ceased when the participant coughed five times following a single dose of capsaicin (C5) 
or following the maximum dose of 1000 M.  
Leicester Cough Questionnaire. Participants also completed the Leicester Cough Questionnaire 
(LCQ), a validated patient-report outcome measure of cough-related quality-of-life (37, 38). All 
demographic and survey information, including the LCQ, was gathered using the HIPAA-compliant online 
survey platform, Qualtrics.   
Urge-to-Cough Testing. In addition to the LCQ, participants were asked to report their urge-to-
cough (UTC) on a scale from 0 (no UTC) to 10 (maximum UTC) when presented with the following 
stimulants that are common cough triggers in patients with RCC: perfume, bleach, vinegar, laundry soap, 
fabric softener (each held under the nose for 10 seconds), deep and fast breath in through the mouth, 
maximum sustained voicing, reading a 55-word passage, and yelling a short phrase. Number of coughs 
for each stimulant task was also recorded. 
Cough Frequency Testing. Before beginning treatment sessions, participants wore a digital mp3 
audio recorder (i.e., Leicester cough monitor) over a 24-hour period. Digital recordings were stored 
using encrypted cloud technology for future analysis to determine objective cough frequency.    
Treatment procedures  
Cough Suppression Training. Immediately following baseline testing, during the first session, 
participants were instructed on cough suppression strategies. The primary cough suppression strategy 
taught was relaxed-throat breathing. This two-part technique takes advantage of natural reflexes within 
the airway to keep the vocal folds open (42). It consists of a sharp inhale through the nose, followed by a 
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long exhale through pursed lips. The sharp inhale elicits the abductory laryngeal reflex to abduct the 
vocal folds. Exhaling through pursed lips increases intra-oral and intra-laryngeal pressures, thus resisting 
closure of the vocal folds to resist coughing. Participants were asked to complete approximately 10 
relaxed-throat breaths, four times per day before the first treatment session and throughout the 
treatment phase, when not feeling an urge-to-cough, in order to create a strong motor pattern. They 
were also instructed to use the breathing when feeling an urge-to-cough in and outside of therapy 
sessions.   
While participants were given instruction in relaxed-throat breathing, cough suppression was 
the goal, so participants were free to modify the breathing technique to best ensure cough suppression. 
This included modifications including varying rates of the inhale, exhalation methods (through a straw or 
with a hiss), or variations of volume of breath. Because the method varied individually, it will now be 
referred to as cough-control breathing (CCB).  
Active Treatment. Participants attended treatment sessions twice per week, for three weeks, 
with a minimum of 72 hours between each session (required by the FDA). Treatment sessions for 
participants randomized for the active treatment consisted of repeated exposures to aerosolized 
capsaicin combined with cough suppression strategies. The concentration of capsaicin was incrementally 
increased, as tolerated by each participant, to ensure successful cough suppression following each 
exposure. Spirometry was performed before and after each session to ensure participants were safe to 
begin treatment and pulmonary function remained unchanged following treatment. The first session 
began one capsaicin concentration below the participant’s highest concentration at baseline testing (i.e., 
C5 threshold). After receiving the capsaicin via a single inhale, participants were instructed to complete 
his/her breathe in, and then immediately begin cough-control breathing (CCB) to suppress the cough. 
Participants were also allowed to take a sip of water during the suppression period if they wished. 
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Participants were asked to indicate their UTC by pointing to the visual-analog UTC scale immediately 
after receiving the dose. They were also asked to indicate their discomfort on a 0 (no discomfort) to 10 
(maximum discomfort) visual-analog scale.   They were asked not to speak for at least 15 seconds to 
ensure that any UTC was elicited by the capsaicin and not talking. Participants received 1-4 trials of each 
capsaicin concentration before increasing the concentration. The concentration was increased when the 
participant appeared to be able to suppress the current concentration without significant effort. Initial 
study protocol limited capsaicin exposure to six individual exposures within a treatment session; 
however, it was soon recognized that this limited progress  because participants were so sensitive they 
hardly advanced in concentration within a session. Exposure rate was, therefore, increased to 12 
concentrations a session after the initial eight subjects. Each treatment session started at the capsaicin 
concentration one level below the prior session’s maximum suppressed concentration.   
Placebo Treatment. The placebo group underwent the same procedures, including number of 
sessions, spirometry, inhalation of aerosolized substance, and relaxed throat-breathing; however, 
placebo participants received a sub-threshold concentration of capsaicin (i.e., a concentration that did 
not elicit cough), as determined during baseline testing, and the concentration never increased 
throughout the treatment phase. The placebo participants were asked to complete five trials of relaxed-
throat breathing immediately following each exposure. The nebulizer was rinsed in between each 
application to avoid participants from suspecting that they were in the placebo group. The initial three 
placebo group participants received six exposures per session, while the remaining placebo participant 
received 10-12 exposures per session, in accordance with the increase in exposure frequency for the 
treatment group.  
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Data Collection and Analysis  
 Data was collected using a variety of methods. The LCQ, was collected using Qualtrics, a HIPAA-
compliant survey software. UTC and cough challenge data were administered and recorded within in-
person sessions, then moved to secure, HIPAA-compliant cloud storage. Cough frequency recordings 
were downloaded from Sony digital recorders and also moved to secure cloud storage.  
 Statistical analysis was performed with the IBM Statistical Package for the Social Sciences (SPSS) 
software. Both research questions sought to highlight differences in cough outcomes (i.e., cough 
sensitivity, cough frequency, and cough-related quality of life) following treatment. Due to the small 
sample size, non-parametric tests were chosen. A Mann-Whitney U test on change-scores was used to 
determine between-group differences from baseline to one-week post-treatment, and from one-week 
post-treatment to three-weeks post-treatment.  A Friedman test followed by pair-wise comparisons 
with Bonferroni correction (as applicable) was used to analyze differences of the entire sample across 
time.  
Results 
 Fifteen participants enrolled in the study. Three participants were unable to complete the study 
due to illness unrelated to the study; no adverse effects were reported throughout the study. Out of the 
twelve participants who completed the study, four were in the placebo group, and eight were in the 
treatment group. Participant demographics are shown in Table 1.  Cough frequency data from the 24-
hour Leicester Cough Monitoring has to be analyzed by Dr. Sirrinder Birring’s lab in the United Kingdom 
and has not yet been obtained.  Hence, 24-hour cough frequency will not be included in the analysis or 
discussed further.  
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Table 1. Participant demographics.  
Participant Gender Age Cough duration 
P1 M 89 > 2 years 
P2 F 63 > 2 years 
P3 F 75 > 2 years 
P4 F 60 > 2 years 
P5 F 72 > 2 years 
P6 F 71 > 2 years 
P7 F 62 > 2 years 
P8 F 72 18-24. months 
P9 F 28 12-18 months 
P10 F 50 4-6 months 
P11 F 66 > 2 years 
P12 F 76 > 2 years 
 
Given the small sample size, nonparametric statistical tests were used to analyze the data. 
Cough sensitivity data (i.e., capsaicin concentration causing five or more coughs (C5) during cough 
challenge testing) were converted to log form. Change scores were then created by calculating the 
difference between baseline and one-week post-treatment scores on the LCQ, UTC, cough count during 
UTC testing, and logC5. Change scores were also calculated for the difference between post-test 1 (one-
week post-treatment) and post-test 2 (three-weeks post-treatment) to assess maintenance of change 
during the post-test period. Outcomes across time for each participant as well as change scores for 
these measures are shown in Tables 2 and 3. A Mann Whitney U test was used to determine if there 
were differences in the change scores for each measure (i.e., LCQ, UTC, cough count, and logC5) 
between the treatment group and placebo group. Results are displayed in Table 4. 
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Table 2. Participant outcomes for the Leicester Cough Questionnaire and urge-to-cough testing.  
Participant 
Leicester Cough Questionnaire: total 
score Urge-cough-testing sum total coughs 
Urge-to-cough testing average 
reported UTC 
 Baseline 
Post-
test 1 
Post
-test 
2 △ 1 △ 2 Baseline 
Post-
test 1 
Post-
test 
2 △ 1 △ 2 Baseline 
Post
-
test 
1 
Post-
test 
2 △ 1 △ 2 
Placebo 
group 
               
P1 
17.54 18.4 18 0.9 -0.4 0 0 0 0 0 0 0 0.15 0 0.2 
P2 
12.76 14.5 15.4 1.7 0.9 0 0 0 0 0 0.7 0.9 0.65 0.2 -0.3 
P3 
11.68 9.0 10.4 -2.7 1.4 2 12 0 10 -12 3.4 1.85 0.35 -1.6 -1.5 
P4 
12.55 17.7 18.4 5.2 0.7 28 1 4 -27 3 2.3 0.15 0.5 -2.2 0.4 
Treatment 
group 
               
P5 
14.46 15.8 17.9 1.3 2.1 0 0 1 0 1 0.3 0.05 0.15 -0.3 0.1 
P6 
14.87 17.9 17 3.0 -.9 9 0 0 -9 0 1.35 0 0.05 -1.4 0.1 
P7 
11.57 16.0 16.5 4.4 0.5 2 1 1 -1 0 1.9 0.25 0.2 -1.7 -0.1 
P8 
11.46 13.6 16.7 2.1 3.1 3 0 0 -3 0 1.3 0 0.3 -1.3 0.3 
P9 
11.32 16.6 15.1 5.3 -1.5 45 8 1 -37 -7 4.85 2.55 1.4 -2.3 -1.2 
P10 
15.33 16.7 18.4 1.4 1.7 48 11 0 -37 -11 4.4 1.8 1.45 -2.6 -0.4 
P11 
7.785 9.0 8.8 1.2 -0.2 8 0 0 -8 0 1.85 0.05 0 -1.8 -0.1 
P12 15.12 16.04 
 
Note. △1= change between baseline and post-test 1. △2= change between post-test 1 and post-test 2. 
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Table 3. Participant outcomes for cough challenge testing 
Participant 
Baseline 
 
Post-test 1 
 
Post-test 2 
 Log Change 
Scores 
C5 
(mol/L) 
log 
C5 
 
C5 (mol/L) log C5 
 C5         
(mol/L) log C5 
 
△ 1 △ 2 
Placebo 
group 
           
P1 3.91 0.59  0.49 -0.31  15.63 1.19  -0.90 1.50 
P2 7.81 0.89  3.91 0.59  7.81 0.89  -0.30 0.30 
P3 15.63 1.19  7.81 0.89  1.95 0.29  -0.30 -0.60 
P4 0.98 -0.01  0.98 -0.01  3.91 0.59  0.00 0.60 
Treatment 
group 
           
P5 15.63 1.19  31.25 1.49  31.25 1.49  0.30 0.00 
P6 1.95 0.29  0.98 -0.01  1.95 0.29  -0.30 0.30 
P7 7.81 0.89  15.63 1.19  7.81 0.89  0.30 -0.30 
P8 7.81 0.89  15.61 1.19  15.63 1.19  0.30 0.00 
P9 7.81 0.89  31.25 1.49  3.91 0.59  0.60 -0.90 
P10 0.49 -0.31  0.98 -0.01  7.81 0.89  0.30 0.90 
P11 7.81 0.89  7.81 0.89  0.49 -0.31  0.00 -1.20 
P12 0.49 -0.31  3.91 0.59  1.95 0.29  0.90 -0.30 
 
Note. △1= change between baseline and post-test 1. △2= change between post-test 1 and post-test 2. 
 
  The Mann-Whitney U test revealed weak evidence for a greater improvement in LCQ score in 
the treatment group than the placebo group at one-week post-treatment relative to baseline (mean 
rank = 7.13 and 5.25, respectively; U=11, z= -0.849, p=0.23). Weak evidence for greater improvement in 
the treatment group than placebo group during UTC testing for both total coughs (mean rank = 7.19 and 
5.13, respectively; U = 8, z = -1.386, p = 0.107) and mean reported UTC (mean rank = 7.5 and 4.5; 
respectively; U = 10.5, z =-0.936, p=.184) were also found at one week post-treatment. There was no 
evidence of a significant difference between post-test 1 and post-test 2 on LCQ, total coughs, and mean 
UTC (p-value = .933 on each measure).   
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Cough challenge testing (CCT) results were more variable. A statistically significant change in 
logC5 at post-test 1 that favored the treatment group (mean rank = 8.25 and 3.00, respectfully;  U = 2,  
z= -2.382, p = .016) was found; however at post-test 2 logC5 was higher for the placebo group (mean 
rank = 8.5) then the treatment group (mean rank = 5.5), which was inconsistent with all other outcome 
measures (see Figure 1).  This paradox, along with the researcher’s observation of significant variability 
in patients’ responses to varying capsaicin concentrations during treatment sessions and CCT, suggest 
either an error in CCT procedures or reduced reliability and/or validity of CCT.  
Table 4. Results of Mann-Whitney U test.   
 
 
 
 
 
 
 
 
 Baseline to Post-test 1   Post-test 1 to Post-test 2  
U z p 
mean 
rank: 
treatment 
mean 
rank: 
placebo 
 
U z p 
mean 
rank: 
treatment 
mean 
rank: 
placebo 
Leicester 
Cough 
Questionnaire 
11 -0.849 0.23 7.13 5.25  15 -0.2 0.933 6.63 6.25 
Urge-to-
cough: total 
coughs during 
testing 
8 -1.386 0.107 7.5 4.5  15 -0.2 0.933 6.63 6.25 
Urge-to-
cough: 
average 
reported UTC 
during testing 
10.5 -0.936 0.184 7.19 5.13  15 -0 0.933 6.63 6.25 
Cough 
Challenge 
Testing: log 
C5 
2 -2.382 0.008 8.25 3  24 1.36 0.214 5.5 8.5 
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Figure 1. Participant cough challenge testing (CCT) scores 
 
 Given only weak evidence of a difference between groups, and given visual analysis of the data 
suggested that both groups improved (see Figures 2-4), a Friedman test was used to analyze the entire 
sample across time on each measure. Post hoc analyses were performed, when appropriate, using 
pairwise comparisons with a Bonferroni correction for multiple comparisons. 
Figure 2. Leicester Cough Questionnaire (LCQ) total scores  
*Note that LCQ uses inverse scoring, a higher score indicates more positive outcomes. 
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Figure 3. Mean UTC during urge-to-cough testing. 
 
Figure 4. Mean coughs during urge-to-cough testing. 
 
 The Friedman test revealed strong evidence for change in LCQ across time, χ2(2)=13.167, p = 
.001. Post hoc pairwise comparisons with Bonferroni correction revealed significant improvement in LCQ 
scores from baseline to post-test 1 (p= 0.024) and baseline to post-test 2 (p = 0.002), and no evidence of 
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change between post-test 1 and post-test 2 (p = 1.00).  Average reported UTC during UTC testing was 
the same with significant change across time (χ2(2) = 10.186, p = .006), and post-hoc analysis revealing 
significant improvement between baseline and post-test 1 (p = .043) and baseline to post-test 2 (p = 
.018), but no evidence of a change between post-test 1 and post-test 2 (p = 1.00). Total coughs during 
UTC testing followed a similar pattern. Freidman test revealed significant change across time, χ2(2) = 
8.323, p = .016.  Post hoc pairwise comparisons with Bonferroni correction revealed moderate evidence 
for improvement from baseline for both post-test 1 (p = .199) and post-test 2 (p = .096), and no 
evidence of a change between post-test 1 and post-test 2 (p = 1.00). Freidman test on logC5 did not 
reveal evidence of a change across time, χ2(2) = .744, p = .689, therefore post-hoc analysis was not 
necessary.  
Table 5. Results of the Friedman test and post hoc pair-wise comparisons with Bonferroni correction. 
 χ2(2) p 
Mean rank 
 
P-value of pair-wise 
comparisons 
baseline 
post-
test 1 
post-
test 2 
 
△1 △2 △3 
Leicester Cough 
Questionnaire 
13.167 0.001 1.17 2.25 2.58  0.024 0.002 1 
Urge-to-cough: total 
coughs during testing 
8.323 0.016 2.54 1.79 1.67  0.199 0.096 1 
Urge-to-cough: average 
reported UTC during 
testing 
10.186 0.006 2.71 1.71 1.58  0.043 0.018 1 
Cough Challenge 
Testing: log C5 
0.744 0.689 1.83 2 2.17  n/a n/a n/a 
Note. △1 = change between baseline and post-test 1. △2 = change between baseline to post-test 2. △3 
= change between post-test 1 to post-test 2 
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Discussion 
 The purpose of this study was to determine if a novel treatment, which we call cough 
desensitization treatment (CDT), may be effective for patients with refractory chronic cough (RCC) who 
fail standard medical treatment and traditional behavioral cough intervention. CDT combines principles 
of programmatic desensitization with behavioral cough suppression to target cough hypersensitivity that 
is thought to be the underlying cause of RCC. We hypothesized that this clinically controlled treatment 
would benefit patients whose cough is so severe they cannot suppress it when exposed to 
environmental stimuli, making traditional behavioral cough suppression therapy ineffective. Our 
previous research demonstrated a change in cough sensitivity, as measured by cough challenge testing 
with capsaicin, with CDT in healthy participants (27). In this study, we expanded outcome methodology, 
adding a cough-related quality of life measure and urge-to-cough testing. We also added a placebo 
group and random group assignment.  
Despite the small sample size, results generally support our hypothesis. There was a significant 
improvement in cough-related quality of life and perceived urge-to-cough to a variety of common cough 
triggers between baseline testing and post-testing for both groups, and weak evidence for a greater 
improvement in the treatment group versus the placebo group. Overall, half (2/4) of placebo 
participants and all but one (7/8) of the treatment participants reported clinically relevant improvement 
on both of these measures. We did not anticipate the improvement in both groups, and it is important 
to note that the placebo group had one significant outlier whose improvement likely skewed group data. 
There are also several potential reasons for the improvement of both groups, rather than just the 
treatment group. The first, and most likely, is that compliance to behavioral therapy may have increased 
during the study compared to previous behavioral therapy. Assignment of a self-report cough-control 
breathing practice log and cough-suppression-effectiveness log, turned in at each session, may have 
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increased patient motivation and compliance. Each participant also received six treatment sessions, an 
increase over the reported average of 1-4 sessions typically provided in traditional behavioral therapy 
(10, 20, 30). Another possible reason for the improvement of the placebo group is the effect of capsaicin 
desensitization.  Given that the placebo group received capsaicin albeit at a lower dose, it is possible 
that the improvement was due to desensitization from repeated low-level exposure. Current literature 
describes tachyphylaxis in single-inhalation cough challenges lasting no more than a few minutes (43-
45), which lead us to hypothesize that repeated exposure alone would not result in long term 
desensitization.  However, to our knowledge, no prior studies have investigated repeated exposure to 
subthreshold doses, making the possibility of long-term desensitization in this scenario unknown. If the 
improvement was due to desensitization, we would expect it to be reflected in cough challenge testing 
(CCT), which we did not see; however, high variability within subjects lead us to question the reliability 
of the measure for this particular population or with our particular procedures. We explored this 
phenomenon by attempting to verify the C5 point (i.e., the dose that causes five coughs). After the C5 
concentration was found, we repeated that same concentration a second time. If the participant 
coughed five or more times, we ceased testing; if they coughed less than five times, we continued the 
testing with the doubling doses until we found the next concentration that caused five or more coughs. 
We found that participants were often able to tolerate a much higher concentration than the initial C5 
point, even when instructed not to suppress coughs. For example, in one cough-challenge post-test, a 
subject who initially reached C5 at 7.8125 mol/L capsaicin, only coughed two times with a second 
administration of 7.8125 mol/L (with a two minute delay between repetitions) and did not cough five 
or more times again until she reached 125 mol/L, though she did experience a few coughs over the 
progressive doses. There have been several noted issues with capsaicin cough challenge testing, 
including a “startle response” which may have attributed to the phenomenon in our example, as well as 
noted differences between male and female responses (40, 46). Additionally, CCT reproducibility 
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guidelines for reliability and stability of CCT have only been performed with healthy individuals (34, 40, 
41).  These factors lead us to question the reliability of cough challenge testing in our study.  
The exact cause of the unreliability of CCT in this study is unclear. Procedures outlined by the 
European Respiratory Society (ERS) were followed exactly with one exception; we did not weld the 
nebulizer straw and baffle together to limit variability in straw and baffle distance across repeated 
administrations, which may have resulted in variation in amount of aerosol particles expelled per 
inhalation (35, 40). This recommendation was inadvertently overlooked when designing the CCT 
procedures. A regulator valve, also recommended by the ERS to limit variability, was used, which lead us 
to believe we had taken appropriate measures to ensure reliability across administrations. There is not 
clear evidence in the literature that welding the straw and baffle together is essential to ensure 
consistent dosimeter output; however, the variability in CCT data in our study does suggest this.  Future 
studies in our lab with the straw and baffle welded compared to our current data will help answer this 
question.  
 The most obvious limitation in this study is the small sample size, particularly the small placebo 
group, which included a significant outlier that skewed the data. Another limitation includes changing 
the treatment intensity midway (i.e., doubling the treatment practice participants received).  
Future Directions    
While the experimental groups did not demonstrate significant differences, both groups did 
show significant improvement in self-report measures over time. This improvement warrants further 
investigation, to determine what pieces of therapy led to the success. To specifically explore the impact 
of repeated capsaicin exposure coupled with cough suppression, potential changes to the research 
design include adding a “true” placebo group that receives saline instead of a sub- threshold dose of 
capsaicin and eliminating the instruction to suppress cough outside of the therapy room for both 
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groups. It is also necessary to investigate variation in treatment intensity by modifying exposures to 
capsaicin or sessions. It is likely that a one-size-fits-all approach, as investigated in this study, is not the 
most optimal approach to CDT. Rather, we suspect that optimal treatment intensity will be dictated by 
patient response.    
Cough desensitization treatment (CDT), examined in this study, had clear benefits for the 
majority of patients with RCC in our study. Although further refinement of treatment procedures is 
necessary for optimal outcomes, CDT could prove a useful option for patients with RCC who have 
exhausted medical options, and failed traditional behavioral cough suppression.  
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Appendix A 
SUBJECT INFORMATION AND INFORMED CONSENT 
Study Title: A pilot study of cough reflex desensitization for the treatment of cough hypersensitivity 
syndrome  
Investigator:  
Laurie Slovarp Ph.D., Associate Professor, University of Montana, Department of Communicative 
Sciences and Disorders (CSD 031), (406) 243-2107 
Special Instructions:  
This consent form may contain words that are new to you.  If you read any words that are not clear to 
you, please ask the person who gave you this form to explain them to you. 
Inclusion Criteria: 
• At least 18 years of age 
• Currently suffering from a cough that started at least 8 weeks ago 
• Have seen at least one physician for the cough and have received medical treatment 
without success 
• Normal chest x-ray, pulmonary function testing, and laryngoscopy (completed by your 
physician or a qualified speech-language pathologist)  
• Have undergone behavioral cough suppression therapy without full resolution of cough 
• Willing to take a pregnancy test before enrollment (if applicable) 
• Willing to use contraception during the study (if applicable; we will not be able to supply 
you with contraceptive methods) 
• Willing to sign an informed consent form 
 
Exclusion Criteria:  
• Under 18 years of age 
• Currently a smoker of any substance 
• Pregnant or attempting to become pregnant 
• Diagnosed with a respiratory or pulmonary condition (e.g., asthma, COPD, emphysema, 
lung cancer, bronchitis) 
• Suffering from any signs of upper respiratory illness 
• Taken any of the following medications within the past month: 
o lisinopril/Prinivil/Zestril 
o captopril/Capoten 
o enalapril/Epaned/Asotec, ramipril/Altace 
o benazepril/Lotensin 
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o fosinopril/Monopril 
o moexipril/Univasc 
o perindopril/Aceon 
o quinapril/Accupril 
o trandolapril/Mavik  
Purpose 
The purpose of this research is to investigate a new treatment for chronic cough.  The treatment 
involves implementing behavioral cough suppression therapy (BCST) combined with inhalation of a 
substance designed to enhance the effect of BCST.  BCST is a therapy that teaches patients a variety of 
techniques that help suppress cough. Suppressing the cough over time helps reduce cough sensitivity. 
One drawback of BCST is that it can be difficult for some patients to suppress their cough, which 
prevents the therapy from working. The substance being tested in this study is designed to improve 
patients’ ability to suppress their cough. The use of this substance has been deemed safe for this specific 
research study by the FDA.  
In order to determine if this new therapy works, we will include a placebo treatment (an inactive 
treatment). Adding a placebo group is a common research practice that helps researchers rule out a 
placebo effect (when patients improve after getting a treatment simply because they believe the 
treatment will work).  You will not know what treatment group you are in. If you are selected to be in 
the placebo group (which we will inform you of after you’ve completed the study), and the active 
treatment is shown to be effective, you will have the option to receive the active treatment at the end 
of the study. Clinically relevant research results may be shared with you at the end of the study and we 
will provide you with a copy of any publications that result from this study.  
Procedures  
If you choose to participate in this study, you will be asked to follow the following procedures, which will 
take place across six weeks. All sessions will take place in the VOICES lab at the University of Montana 
(Curry Health Center, room 040). 
1. WEEK 1: BASELINE TESTING AND TRAINING (approximate time = 1 hour).  
a. Cough sensitivity testing: Standardized procedures that have been approved by 
the FDA will be used to determine your cough sensitivity. You will inhale 
capsaicin mist (a known cough stimulant) through a small device called a 
nebulizer that delivers a specific amount of capsaicin, during a single inhale, in a 
mist form. You will inhale between 2-12 different doses (i.e., concentrations) of 
capsaicin mist, starting with a .49 micromolar concentration and increasing by 
double with each subsequent exposure. The maximum dose will be 1000 
micromolar. The testing will stop when we find the dose that causes you to 
cough five times or when we give you the 1000 micromolar dose, whichever 
comes first. This testing will take approximately 30 minutes.  
b. Urge-to-cough (UTC) testing: You will be asked to report your subjective UTC on 
a scale from 0 (no UTC) to 10 (maximum UTC) after each mist of capsaicin and 
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after being presented with various stimulants/tasks that cause some people to 
cough (e.g., perfumes, cleaning supplies, deep breath, yelling). This testing will 
take about 10 minutes.  
c. Cough-related quality of life:  You will answer 23 questions designed to measure 
how your cough is impacting your quality of life. This will take about 5 minutes.  
d. Cough suppression training. You will be trained in cough suppression strategies. 
These strategies include 1) relaxed throat breathing where you inhale quickly 
through your nose and exhale through tightly pursed lips or while saying “sssss”, 
and 2) cough suppression swallow, which involves swallowing your saliva or a sip 
of water with as much effort as possible and while pressing your hands together 
tightly. This training will take approximately 15 minutes.  
e. Cough frequency testing: You will carry a small audio recording device with a 
small microphone that attaches to your shirt for 24 hours. The recording device 
will be in a small carrying case (about half the size of a typical cell phone) that 
can clip to your belt or waistband. You will return the recording device to us at or 
before your first treatment visit (see below). The audio recording will be 
analyzed by computer software that counts the number of times you coughed in 
the 24-hour period.  (NOTE: The audio recording will not be listened to by any 
PERSON and the recording will be deleted after it is analyzed by the computer 
software.) 
 
2. WEEKS 2-4: TREATMENT. You will attend treatment sessions twice per week for three 
weeks. You will use the breathing strategies following inhalation of either the active 
substance or the placebo. You will do this no more than six times per session. Each 
session will take approximately 45 minutes. If you miss a treatment session, we will 
attempt to re-schedule that session. You must complete at least five of the sessions to 
remain in the study.  
 
3. WEEKS 5 AND 7: POST-TREATMENT TESTING. Cough sensitivity, urge-to-cough, and 
cough-related quality of life will be measured, just as they were in the baseline phase, at 
one-week and three-weeks after your final week of treatment. Cough frequency will be 
measured at one-week post treatment but not at three-weeks post treatment.  
 
4. 3 MONTHS: POST-TREATMENT FOLLOW UP: Cough-related quality of life data will be 
obtained again at 3 months post testing. You will answer 23 questions designed to 
measure how your cough is impacting your quality of life. This will take about 5 minutes. 
Please initial your preferred method of contact.  
Initial which method you would like to be contacted for follow up data.  
 
______ Email: ________________________________________ 
______Phone: _________________________________________ 
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______Mail: __________________________________________ 
          __________________________________________ 
          __________________________________________ 
Risks/Discomforts 
This study includes repeated inhalation of small doses of diluted capsaicin. Capsaicin is the ingredient 
found in many chili peppers that make them spicy. Studies have shown an increased risk of certain types 
of cancer with large doses of capsaicin (i.e., above 100 mg/kg of body weight), while low-dose capsaicin 
has been shown to have an anti-cancer effect. Some studies have also shown a slight risk of 
bronchospasm (e.g., tightening of the muscles that line the airway) following inhalation of capsaicin. 
Bronchospasm is a temporary, treatable condition. We will monitor your breathing carefully. If you 
display symptoms of bronchospasm, we will promptly consult a physician and provide appropriate 
monitoring and treatment. If your symptoms appear emergent, we will call 911. If your symptoms are 
not emergent, we will consult with a doctor at Rocky Mountain ENT clinic or a doctor of your choice. The 
doses used in this study are extremely small and have been shown to be safe in multiple research 
studies. Concentrations of capsaicin in this study will not exceed 1000 micromolar. 
You may or may not experience slight discomfort when inhaling the active substance or placebo 
substance. Discomfort is anticipated to be no more than disliking the taste or the mild discomfort from 
potential coughing. You also may experience a temporary burning sensation similar to what you 
experience when you eat a spicy food. Doses are very small and given incrementally and not everyone 
experiences discomfort or tastes the substance. If you do experience any side effects, they typically are 
gone within one minute of inhaling the substance. We will ask you to indicate your discomfort after each 
inhalation on a visual analog scale from 0 (no discomfort) to 10 (maximum discomfort).  We will ask you 
to take a sip of water in between each dose and take short breaks throughout the sessions, if needed. 
We will carefully moniter your discomfort and will discontinue the treatment if your discomfort appears 
significant. Additionally, you may refuse to continue during any individual session and you may drop out 
of the study at any time, without penalty. 
Benefits 
Your cough may improve as a result of this treatment, but that cannot be guaranteed.  If you received 
the placebo without any benefit, and the active treatment was found to be effective, you will be eligible 
to receive the active treatment, at no charge, after the study has been completed. Whether your cough 
improves or not, you will be contributing to the scientific knowledge base of treatment for chronic 
cough.  
 
Confidentiality 
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Your identity and the information that is obtained about you during this study will remain confidential to 
the extent provided by law.  If the study results are published or presented, your name will not be used. 
Your identification on all documents pertaining to the research will be kept in a locked file cabinet in 
room in the VOICES lab in the Department of Communicative Sciences and Disorders.  The data collected 
during the study will be entered into an excel spreadsheet and will be coded by an anonymous number. 
Your de-identified information will not be used in future research without your consent, and your 
information will not be shared with other investigators.  
Compensation for Injury: 
In the event that you are injured as a result of this research you should individually seek appropriate 
medical treatment.  If the injury is caused by the negligence of the University of Montana or any of its 
employees, you may be entitled to reimbursement or compensation pursuant to the Comprehensive 
State Insurance Plan established by the Department of Administration under the authority of M.C.A., 
Title 2, Chapter 9.  In the event of a claim for such injury, further information may be obtained from the 
University’s Risk Manager (406-243-2700) or the Office of Legal Counsel (406-243-4742; 
legalcounsel@umontana.edu).  (Reviewed by University Legal Counsel, May 9, 2013) 
Voluntary Participation/Withdrawal: 
Your decision to take part in this research study is entirely voluntary. You may refuse to take part in or 
you may withdraw from the study at any time, without penalty. You may be asked to leave the study for 
any of the following reasons: 
1. Failure to follow the project instructions; 
2. You cancel more than one treatment session without re-scheduling; 
    2. A serious adverse reaction, which may require evaluation; 
    3. The Project Director thinks it is in the best interest of your health and welfare; or 
    4. The study is terminated. 
Alternative Treatment Clause 
If your cough does not adequately improve with this experimental treatment, and you have not tried a 
neuromodulator medication (e.g., Gabapentin, Neurontin, Amytriptiline) in the past, you may want to 
consult with your physician about trying a neuromodulator, which have been shown to reduce cough in 
some patients when all other therapies have failed.  
Clinically Relevant Research Results 
The clinically relevant research results, including individual research results, may be disclosed to 
participants following completion of the study. In the event of publication of results from this study, a 
copy of the article will be shared with participants.  
Questions: 
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If you have any questions about the research now or during the study, please contact the Project 
Director: Laurie Slovarp, PhD at (406) 243-2107 or at laurie.slovarp@umontana.edu  
If you have any questions regarding your rights as a research subject, you may contact the UM 
Institutional Review Board (IRB) at (406) 243-6672. 
Statement of Consent for Video Recording (optional) 
My initials below indicate my consent regarding video recording. Please initial all that apply. 
______ I do NOT give my consent to be video recorded.  
______I consent to being video recorded. 
______I consent to use of my video in presentations related to this study. 
______I understand that if video recordings are used for presentations of any kind, names or 
other identifying information will not be associated with them.  
______I consent to using my video recordings for training students or research assistants. 
______I understand that the video recordings will be deleted within 24 months after they have 
been obtained. 
Ethnicity Data:  
Which of the following ethnicity categories best describes you?  
o American Indian/Alaska Native 
o Asian 
o Native Hawaiian or other Pacific Islander 
o Black/African American 
o White 
o Hispanic or Latino 
o More than one race 
o I would rather not say  
Statement of Your Consent: 
I have read the above description of this research study. I have been informed of the risks and benefits 
involved, and all my questions have been answered to my satisfaction.  Furthermore, I have been 
assured that any future questions I may have will also be answered by a member of the research team.  I 
voluntarily agree to take part in this study.  I understand I will receive a copy of this consent form. 
                                                               ____________________________   _______________  
Printed Name of Participant   Signature of Participant      Date 
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Appendix B 
Running head: DESENSITIZATION OF THE COUGH REFLEX  
 
Appendix C 
Cough Desensitization Exploratory Study: Pre-Test Data Sheet 
Participant name: ________________________________  
Relaxed-throat breathing compliance (10 breaths, 4x/day for 4 days) (write in exact or circle estimate):   ________________     <50%      50-70%     70-90%     >90% 
Date: 
 
 
FVC FEV1 FEV1/FVC FIF50% 
FVC FEV1 FEV1/FVC FIF50% 
Dose UTC Cough count Level of discomfort Comments 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
Post tx:  FVC FEV1 FEV1/FVC FIF50% 
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Cough Desensitization Study: Treatment Data Sheet 
Participant name: ________________________________  
Relaxed-throat breathing compliance (10 breaths, 2x/day for 4 days) (write in exact or circle estimate):   ________________     <50%      50-70%     70-90%     >90% 
Date: 
 
 
 
Session: 
 
FVC 
 
 
FEV1 FEV1/FVC FIF50% Date:  
 
 
 
Session: 
FVC FEV1 FEV1/FVC FIF50% 
FVC FEV1 FEV1/FVC FIF50% FVC FEV1 FEV1/FVC FIF50% 
Dose UTC Cough count 
Level of 
discomfort 
Comments Dose UTC Cough count 
Level of 
discomfort 
Comments 
1     1     
2     2     
3     3     
4     4     
5     5     
6     6     
7     7     
8     8     
9     9     
10     10     
11     11     
12     12     
13     13     
14     14     
15     15     
Post tx:  FVC FEV1 FEV1/FVC FIF50% Post tx:  FVC FEV1 FEV1/FVC FIF50% 
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Cough Desensitization Study: Treatment Data Sheet 
Participant name: ________________________________  
Relaxed-throat breathing compliance (10 breaths, 2x/day for 4 days) (write in exact or circle estimate):   ________________     <50%      50-70%     70-90%     >90% 
Date: 
 
 
 
Session: 
 
FVC 
 
 
FEV1 FEV1/FVC FIF50% Date:  
 
 
 
Session: 
FVC FEV1 FEV1/FVC FIF50% 
FVC FEV1 FEV1/FVC FIF50% FVC FEV1 FEV1/FVC FIF50% 
Dose UTC Cough count 
Level of 
discomfort 
Comments Dose UTC Cough count 
Level of 
discomfort 
Comments 
1     1     
2     2     
3     3     
4     4     
5     5     
6     6     
7     7     
8     8     
9     9     
10     10     
11     11     
12     12     
13     13     
14     14     
15     15     
Post tx:  FVC FEV1 FEV1/FVC FIF50% Post tx:  FVC FEV1 FEV1/FVC FIF50% 
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Cough Desensitization Study: Treatment Data Sheet 
Participant name: ________________________________  
Relaxed-throat breathing compliance (10 breaths, 2x/day for 4 days) (write in exact or circle estimate):   ________________     <50%      50-70%     70-90%     >90% 
Date: 
 
 
 
Session: 
 
FVC 
 
 
FEV1 FEV1/FVC FIF50% Date:  
 
 
 
Session: 
FVC FEV1 FEV1/FVC FIF50% 
FVC FEV1 FEV1/FVC FIF50% FVC FEV1 FEV1/FVC FIF50% 
Dose UTC Cough count 
Level of 
discomfort 
Comments Dose UTC Cough count 
Level of 
discomfort 
Comments 
1     1     
2     2     
3     3     
4     4     
5     5     
6     6     
7     7     
8     8     
9     9     
10     10     
11     11     
12     12     
13     13     
14     14     
15     15     
Post tx:  FVC FEV1 FEV1/FVC FIF50% Post tx:  FVC FEV1 FEV1/FVC FIF50% 
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Cough Desensitization Exploratory Study: Post-Test Data Sheet 
Participant name: ________________________________  
Relaxed-throat breathing compliance (10 breaths, 4x/day for 4 days) (write in exact or circle estimate):   ________________     <50%      50-70%     70-90%     >90% 
Date: 
 
 
 
Session: 
 
FVC 
 
 
FEV1 FEV1/FVC FIF50% Date:  
 
 
 
Session: 
FVC FEV1 FEV1/FVC FIF50% 
FVC FEV1 FEV1/FVC FIF50% FVC FEV1 FEV1/FVC FIF50% 
Dose UTC Cough count 
Level of 
discomfort 
Comments Dose UTC Cough count 
Level of 
discomfort 
Comments 
1     1     
2     2     
3     3     
4     4     
5     5     
6     6     
7     7     
8     8     
9     9     
10     10     
11     11     
12     12     
13     13     
14     14     
15     15     
Post tx:  FVC FEV1 FEV1/FVC FIF50% Post tx:  FVC FEV1 FEV1/FVC FIF50% 
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Appendix D 
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UTC Testing 
Patient ID:  
Remind patient: DO NOT SUPPRESS YOUR COUGH 
Wait until the patients UTC returns to baseline after each trigger. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UTC Cough count Comments: 
Baseline    
Laundry Detergent    
Bleach    
Fabric Softener    
Pinesol    
Perfume    
Deep inhale    
Max phonation    
Yell    
Grandfather Passage    
Exercise (self-report)    
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 UTC Cough count Comments: 
Baseline    
Laundry Detergent    
Bleach    
Fabric Softener    
Pinesol    
Perfume    
Deep inhale    
Max phonation    
Yell    
Grandfather Passage    
Exercise (self-report)    
